덱스메데토미딘의 임상적인 사용 = Dexmedetomidine: Clinical use

다국어 초록 (Multilingual Abstract)

Dexmedetomidine is a potent alpha-2-adrenergic agonist, more selective than clonidine, with widespread actions on the mammalian brain. A large body of recent work supports its analgesia and sympatholytic properties. Dexmedetomidine is a useful medication with many clinical applications. The medication has shown efficacy in decreasing the need for opioids, benzodiazepines, propofol, and other sedative medications. Dexmedetomidine has been used effectively for sedation during invasive procedures and in the ICU. Short-term sedation has been shown to be safe in studies, although hypotension and bradycardia are the most significant side effects. Dexmedetomidine is emerging as an effective therapeutic agent in the management of a wide range of clinical conditions with an efficacious, safe profile.

참고문헌 (Reference)

1 Ruesch S, "Treatment of persistent tachycardia with dexmedetomidine during off-pump cardiac surgery" 95 : 316-318, 2002

2 But AK, "The effects of pre-operative dexmedetomidine infusion on hemodynamics in patients with pulmonary hypertension undergoing mitral valve replacement surgery" 50 : 1207-1212, 2006

3 Nelson LE, "The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects" 98 : 428-436, 2003

4 Drouot X, "Sleep in the intensive care unit" 12 : 391-403, 2008

5 Koroglu A, "Sedative, haemodynamic and respiratory effects of dexmedetomidine in children undergoing magnetic resonance imaging examination: Preliminary results" 94 : 821-824, 2005

6 Borgeat A, "Sedation and regional anesthesia" 22 : 678-682, 2009

7 Lerch C, "Sedation and analgesia" 55 : 76-95, 1999

8 Venn RM, "Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit" 54 : 1136-1142, 1999

9 Roche Campo F, "Poor sleep quality is associated with late noninvasive ventilation failure in patients with acute hypercapnic respiratory failure" 38 : 477-485, 2010

10 Panzer O, "Pharmacology of sedative-analgesic agents: Dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists" 29 : 587-605, 2011

11 Brummett CM, "Perineural dexmedetomidine added to ropivacaine causes a dose-dependent increase in the duration of thermal antinociception in sciatic nerve block in rat" 111 : 1111-1119, 2009

12 Herr DL, "ICU sedation after coronary artery bypass graft surgery: Dexmedetomidinebased versus propofol-based sedation regimens" 17 : 576-584, 2003

13 Kauppila T, "Effect of systemic medetomidine, an alpha 2 adrenoceptor agonist, on experimental pain in humans" 74 : 3-8, 1991

14 Shukry M, "Does dexmedetomidine prevent emergence delirium in children after sevoflurane-based general anesthesia?" 15 : 1098-1104, 2005

15 Gerlach AT, "Dexmedetomidine: An updated review" 41 : 245-252, 2007

16 Elbaradie S, "Dexmedetomidine vs. propofol for short-term sedation of postoperative mechanically ventilated patients" 16 : 153-158, 2004

17 Potts AL, "Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis" 19 : 1119-1129, 2009

18 Ickeringill M, "Dexmedetomidine infusion without loading dose in surgical patients requiring mechanical ventilation: Haemodynamic effects and efficacy" 32 : 741-745, 2004

19 Grant SA, "Dexmedetomidine infusion for sedation during fiberoptic intubation: A report of three cases" 16 : 124-126, 2004

20 Corbett SM, "Dexmedetomidine does not improve patient satisfaction when compared with propofol during mechanical ventilation" 33 : 940-945, 2005

21 Shukry M, "Dexmedetomidine as the primary sedative agent for brain radiation therapy in a 21-month old child" 15 : 241-242, 2005

22 Jalonen J, "Dexmedetomidine as an anesthetic adjunct in coronary artery bypass grafting" 86 : 331-345, 1997

23 Mack PF, "Dexmedetomidine and neurocognitive testing in awake craniotomy" 16 : 20-25, 2004

24 Gabor JY, "Contribution of the intensive care unit environment to sleep disruption in mechanically ventilated patients and healthy subjects" 167 : 708-715, 2003

25 Venn RM, "Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: Patient and clinician perceptions" 87 : 684-690, 2001

26 Kamibayashi T, "Clinical uses of alpha2 -adrenergic agonists" 93 : 1345-1349, 2000

27 Jacobi J, "Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult" 30 : 119-141, 2002

28 Anttila M, "Bioavailability of dexmedetomidine after extravascular doses in healthy subjects" 56 : 691-693, 2003

29 Ard J, "Awake craniotomy with dexmedetomidine in pediatric patients" 15 : 263-266, 2003

30 Frost EA, "Anesthesia in the patient for awake craniotomy" 20 : 331-335, 2007

31 Khan ZP, "Alpha-2 and imidazoline receptor agonists. their pharmacology and therapeutic role" 54 : 146-165, 1999

32 Wijeysundera DN, "Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: A meta-analysis" 114 : 742-752, 2003

33 Aantaa R, "Alpha 2-adrenergic agents in anaesthesia" 37 : 433-448, 1993

34 Yuen VM, "A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine" 105 : 374-380, 2007

35 Koroglu A, "A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging" 103 : 63-67, 2006